Evidence map›Paper›PMID 33139577›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Akt3 induces oxidative stress and DNA damage by activating the NADPH oxidase via phosphorylation of p47

Christos Polytarchou, Maria Hatziapostolou, Tung On Yau, Niki Christodoulou, Philip W Hinds, Filippos Kottakis, Ioannis Sanidas, Philip N Tsichlis

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. ThebioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. miR-29a-3p Regulates Autophagy by Targeting Akt3-Mediated mTOR in SiOInternational journal of molecular sciences · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Targeting Akt in cancer for precision therapy.Journal of hematology & oncology · 2021
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Christos PolytarchouDepartment of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; christos.polytarchou@ntu.ac.uk Philip.Tsichlis@osumc.edu.
Maria HatziapostolouDepartment of Biosciences, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, NG11 8NS Nottingham, United Kingdom.
Tung On YauDepartment of Biosciences, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, NG11 8NS Nottingham, United Kingdom.ORCID 0000-0002-3283-0370
Niki ChristodoulouDepartment of Biosciences, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, NG11 8NS Nottingham, United Kingdom.
Philip W HindsMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Filippos KottakisMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Ioannis SanidasMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.ORCID 0000-0002-9063-6840
Philip N TsichlisDepartment of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; christos.polytarchou@ntu.ac.uk Philip.Tsichlis@osumc.edu.
Tufts Medical Center · USNottingham Trent University · GBTufts University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Differential Regulation of RNA processing by Akt isoformsR01CA186729 · NCI · TUFTS MEDICAL CENTER · PI TSICHLIS, PHILIP N. · 2015 to 2019
$1.8M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA186729
6 · The paper itself

Abstract

Akt activation up-regulates the intracellular levels of reactive oxygen species (ROS) by inhibiting ROS scavenging. Of the Akt isoforms, Akt3 has also been shown to up-regulate ROS by promoting mitochondrial biogenesis. Here, we employ a set of isogenic cell lines that express different Akt isoforms, to show that the most robust inducer of ROS is Akt3. As a result, Akt3-expressing cells activate the DNA damage response pathway, express high levels of p53 and its direct transcriptional target miR-34, and exhibit a proliferation defect, which is rescued by the antioxidant

Indexed as

DNA DamageAnimalsCell LineEnzyme ActivationMiceNADPH OxidasesOxidation-ReductionOxidative StressPhosphoproteinsPhosphorylationProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSuperoxidesAkt3 protein, mouseNADPH Oxidasesneutrophil cytosolic factor 1PhosphoproteinsProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSuperoxidesAkt isoformscancerDNA damageNADPH oxidaseoxidative stress

Identifiers

PMID33139577
PMCPMC7682348
OpenAlexW3096831504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.